CORT

NEW YORK, June 25, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective. For additional information, please visit www.lseg.com. Unlock Your Growth Potential with AlgerFounded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a suite of growth equity separate accounts, mutual funds, ETFs, and privately offered investment vehicles. Alger's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for more than 60 years. For more information, please visit www.alger.com. Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. Alger pays compensation to third party marketers to sell various strategies to prospective investors. London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" "Russell®", "FTSE Russell®" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. View original content to download multimedia:https://www.prnewswire.com/news...

NEW YORK, June 22, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective. For additional information, please visit www.lseg.com. Unlock Your Growth Potential with Alger Founded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a suite of growth equity separate accounts, mutual funds, ETFs, and privately offered investment vehicles. Alger's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for more than 60 years. For more information, please visit www.alger.com. Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. Alger pays compensation to third party marketers to sell various strategies to prospective investors. London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" "Russell®", "FTSE Russell®" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. View original content to download multimedia:https://www.prnewswire.com/new...

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth. Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing advanced immunotherapies aimed at enhancing the immune system's response to cancer and infectious diseases, with a market cap of approximately $7.25 billion. Operations: The company generates revenue of $140.98 million from its segment focused on developing next-generation therapies. Insider Ownership: 28.2% Earnings Growth Forecast: 64.1% p.a. ImmunityBio, a growth-focused company with significant insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Despite expected revenue growth of 47.8% annually, ImmunityBio faces financial challenges with less than a year of cash runway and recent shareholder dilution. Analysts agree on potential stock price appreciation, though the company currently trades significantly below estimated fair value. Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report. Upon reviewing our latest valuation report, ImmunityBio's share price might be too pessimistic. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Li Auto Inc. operates in the energy vehicle market in the People’s Republic of China with a market cap of approximately $14.48 billion. Operations: Li Auto generates revenue primarily from its auto manufacturing segment, totaling CN¥109.37 billion. Insider Ownership: 33% Earnings Growth Forecast: 61.6% p.a. Li Auto, characterized by high insider ownership, is navigating growth amid challenges. The company forecasts a 13% annual revenue increase, outpacing the US market. However, recent earning...

It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have lost about 3.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is United Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for United Therapeutics Corporation before we dive into how investors and analysts have reacted as of late. United Therapeutics’Q1 Earnings & Sales Miss Estimates United Therapeutics reported first-quarter 2026 earnings per share (EPS) of $5.82, which missed the Zacks Consensus Estimate of $6.73. Earnings decreased 12% year over year.The company markets four products for PAH: Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for the treatment of pediatric patients with high-risk neuroblastoma.Revenues in the first quarter totaled $781.5 million, which missed the Zacks Consensus Estimate of $800 million. Revenues decreased 2% year over year. Q1 Results in Detail Combined Tyvaso sales totaled $457.5 million, down 2% year over year due to lower revenues from nebulized Tyvaso. Tyvaso sales fell short of the Zacks Consensus Estimate of $469 million.Tyvaso DPI generated revenues of $330.3 million, climbing 9% year over year due to an increase in patient demand and some pricing benefits.Revenues from nebulized Tyvaso (treprostinil) were $127.2 million, down 22%, primarily due to reduced U.S. demand and weaker international sales, despite modest price increases.Sales of Orenitram rose 12% year over year to $135.6 million, primarily driven by higher volumes sold.Remodulin (including Remunity Pump) sales declined 8% year over year to $126.6 million.Unituxin sales were down 8% year over year to $53.6 million.Adcirca sales were $2.9 million, down 52% year over year.Research and development expenses were $138.2 million in the quarter, down 7% year over year, mainly due to lower milestone payments for drug delivery device technologies, partly offset by higher personnel costs.Selling, general and administrative expenses increased 8% to $184.1 million in the quarter.As of March 31, 2026, UTHR had cash, cash equivalents and investments of $3.8 billion compared with $4.6 billion as of Dec. 31, 2025. The company had no debt. Since the earnings rele...

The United States market has experienced a notable upswing, climbing 1.6% in the last week and up 28% over the past year, with earnings projected to grow by 17% annually. In this environment, growth companies with high insider ownership stand out as potentially attractive investments due to their alignment of interests between management and shareholders and their potential for significant earnings expansion. Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: AIRO Group Holdings, Inc. is a multi-faceted advanced Aerospace and Defense company operating in the United States, Europe, and internationally, with a market cap of $282.38 million. Operations: The company's revenue segments consist of Drones at $77.13 million, Avionics at $6.38 million, and Training at $4.51 million. Insider Ownership: 12.6% Earnings Growth Forecast: 67.2% p.a. AIRO Group Holdings is poised for growth with expected revenue expansion of 28.5% annually, outpacing the US market. Despite a volatile share price, insider transactions show more buying than selling recently. The company is exploring acquisitions to enhance its drone and avionics platforms while planning share repurchases to boost shareholder value. Recent product unveilings highlight AIRO's focus on defense and government applications, with promising advancements in autonomous aircraft technology aimed at commercialization by 2027. Click to explore a detailed breakdown of our findings in AIRO Group Holdings' earnings growth report. In light of our recent valuation report, it seems possible that AIRO Group Holdings is trading behind its estimated value. Simply Wall St Growth Rating: ★★★★★★ Overview: Astera Labs, Inc. designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure with a market cap of $58.77 billion. Operations: The company's revenue primarily comes from its semiconductor segment, amounting to $1.00 billion. Insider Ownership: 10.3% Earnings Growth Forecast: 31.5% p.a. Astera Labs is experiencing rapid growth, with earnings projected to increase significantly at 31.5% annually, surpassing the US market average. Despite recent insider selling, the company’s revenue is expected to grow 26.4% per year, d...

The United States market has shown robust performance, climbing 1.6% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business and can offer significant potential for earnings growth. Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★☆ Overview: REalloys Inc. is a North American company specializing in rare earth metals and permanent magnets, with a market cap of $548.05 million. Operations: The company's revenue is primarily derived from its Metals & Mining - Miscellaneous segment, totaling $0.80 million. Insider Ownership: 31.8% Earnings Growth Forecast: 69.1% p.a. REalloys, with high insider ownership, is poised for significant growth, driven by strategic alliances and innovative technologies. The company recently announced a partnership with Ramaco Resources to secure rare earth materials essential for U.S. strategic sectors. Despite reporting a net loss of US$75.56 million in 2025 and delayed SEC filings, REalloys' revenue is forecasted to grow rapidly at 66.8% annually, outpacing the market average significantly, although share price volatility remains a concern. Navigate through the intricacies of REalloys with our comprehensive analyst estimates report here. Insights from our recent valuation report point to the potential overvaluation of REalloys shares in the market. Simply Wall St Growth Rating: ★★★★★☆ Overview: Streamex Corp. is a medical device technology company that offers advanced digital signal processing solutions for electrophysiology in the United States, with a market cap of $273.53 million. Operations: Streamex Corp. generates its revenue through the provision of advanced digital signal processing solutions specifically designed for electrophysiology applications in the U.S. Insider Ownership: 12.1% Earnings Growth Forecast: 114.5% p.a. Streamex, with substantial insider ownership, is positioned for growth through its innovative tokenized securities platform. The recent launch of a 24/7 secondary liquidity infrastructure in partnership with Orca e...

Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, companies that exhibit high growth potential and significant insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business. Click here to see the full list of 181 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Evolus, Inc. is a performance beauty company that provides products in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia with a market cap of $442.54 million. Operations: The company's revenue segment focuses on delivering medical aesthetic products to the cash-pay aesthetic market, generating $301.79 million. Insider Ownership: 11.1% Earnings Growth Forecast: 66.7% p.a. Evolus, Inc. is poised for significant growth with its forecasted profitability within three years and revenue growth expected to outpace the broader US market at 14.4% annually. Recent earnings show a narrowing net loss, and the company anticipates annual revenues between US$327 million and US$337 million for 2026. The upcoming European launch of Estyme marks an international expansion in dermal fillers, potentially enhancing revenue streams despite historically volatile share prices and negative shareholders' equity concerns. Click here and access our complete growth analysis report to understand the dynamics of Evolus. Our expertly prepared valuation report Evolus implies its share price may be lower than expected. Simply Wall St Growth Rating: ★★★★★★ Overview: Upstart Holdings, Inc. operates a cloud-based AI lending platform in the United States and has a market cap of approximately $2.58 billion. Operations: The company's revenue is primarily derived from its personal lending segment, which generated $1.01 billion. Insider Ownership: 12.8% Earnings Growth Forecast: 58.5% p.a. Upstart Holdings is positioned for robust growth, with earnings projected to rise significantly at 58.5% annually, outpacing the US market. Despite a recent net loss of US$6.65 million in Q1 2026, insider activity indicates more buying than selling over...

In the last week, the United States market has stayed flat, yet it has seen a remarkable 25% increase over the past year with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for continued success. Click here to see the full list of 187 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Aeluma, Inc. develops optoelectronic and electronic devices for sensing, communication, and computing applications in the United States with a market cap of $488.06 million. Operations: The company's revenue is primarily derived from its Semiconductor Equipment and Services segment, which generated $5.23 million. Insider Ownership: 25.8% Earnings Growth Forecast: 68.6% p.a. Aeluma is positioned for significant growth with forecasted revenue expansion of 77% annually, outpacing the US market. Despite a volatile share price and recent net losses, its strategic focus on high-growth sectors like AI infrastructure and quantum technologies is bolstered by substantial U.S. government contracts exceeding US$4 million. The company's innovative quantum dot laser platform, supported by NASA awards, enhances its competitive edge in photonics integration. However, low projected return on equity remains a concern. Click to explore a detailed breakdown of our findings in Aeluma's earnings growth report. Our valuation report here indicates Aeluma may be overvalued. Simply Wall St Growth Rating: ★★★★☆☆ Overview: STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses and accessory delivery systems for the eye, with a market cap of approximately $1.40 billion. Operations: The company's revenue is primarily generated from its ophthalmic surgical products, totaling $239.44 million. Insider Ownership: 26.2% Earnings Growth Forecast: 71.6% p.a. STAAR Surgical's growth potential is underscored by its forecasted revenue increase of 11.8% annually, slightly above the US market average. Recent earnings showed significant improvement with sales reaching US$93.52 million, a substantial rise from the previous year, and a shift to n...

Image source: The Motley Fool. Thursday, July 31, 2025 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff, M.D. President, Endocrinology — Sean Maduck Chief Business Officer — Gary Charles Robb Chief Development Officer — William Guyer President, Oncology — Roberto W. Vieira Chief Financial Officer — Atabak Mokari Need a quote from a Motley Fool analyst? Email [email protected] Our revenue in the second quarter of 2025 was $194.4 million, compared to $163.8 million in the prior year period. We have modified our 2025 revenue guidance to $850 million to $900 million. Net income was $35.1 million compared to $35.5 million in the second quarter of last year. Our cash and investments at June 30 were $515 million. Balance reflects our acquisition of $115 million of our common stock in the second quarter, pursuant to our stock repurchase program, the net exercise of stock options by Corcept employees and the net vesting of restricted stock grants. I'll now turn the call over to Sean Maduck, President of our Endocrinology division. Sean? Sean Maduck: Thank you, Atabak. The endocrinology division had an excellent second quarter. For the sixth quarter in a row, we added a record number of new prescribers and new prescriptions, and there are a record number of patients on therapy. We shipped more tablets to patients than ever before, 49% more than the second quarter last year. Our financial results don't fully reflect the surge in demand. While our quarterly revenue growth was substantial, a $37 million increase over the first quarter, it should have been more. I discussed on the last call the insufficient capacity of our pharmacy vendor. Its capacity has increased in the second quarter but not as much as we expected and not enough to keep pace with our growth. Capacity will increase further in the second half of the year. We dispensed another record number of tablets in July with more increases to follow. We are also bringing online a second pharmacy. You will see the financial impact of this addition in the fourth quarter. Increased pharmacy capacity is important because I'm certain our growth is poised to accelerate. For many years, physicians only screened and treated the most physically obvious cases of hypercortisolism. In the last 15 years, many studies have been published supporting the identification and the treatment across a much broader spectrum of disease...

Image source: The Motley Fool. Thursday, April 30, 2026 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff Chief Financial Officer — Atabak Mokari President, Endocrinology — Sean Maduck President, Oncology — Roberto Vieira Chief Development Officer — William Guyer Need a quote from a Motley Fool analyst? Email [email protected] Our revenue in the first quarter of 2026 was $164.9 million compared to $157.2 million in the prior year period. We have increased our 2026 revenue guidance to $950 million to $1.05 billion. Net loss was $31.8 million in the first quarter of 2026 compared to net income of $20.5 million in the first quarter of last year. Our cash and investments at March 31 were $515 million. I will now turn the call over to Sean Maduck, President of our endocrinology division. Sean? Sean Maduck: Thanks, Atabak. Demand for our medications continues to increase. We ended the first quarter with a record number of new prescriptions written from a record number of prescribers, which translated to an all-time high for the number of patients receiving our medications. Importantly, we set a record for new patient starts in March and again in April. These figures are outstanding and give me great confidence in the current and future health of our hypercortisolism business. The full impact is not reflected in our revenue for 3 reasons. First, revenue often dips in the first quarter as it does for many rare disease medications because insurance companies impose onerous reauthorization procedures at the start of each year that interrupt patient coverage for a month or 2. We provide patients with free drug to bridge the gap, but our revenue suffers. Second, new patients, whom we are adding at a rapid clip, provide much less revenue when they start treatment than they will later after payer coverage has been secured and they have titrated to their optimum dose. The full revenue impact of patients added this quarter will grow substantially over the next few quarters. Finally, our specialty pharmacy vendor has done an excellent job onboarding the thousands of patients transferred from our former vendor and getting them the medicine they've been prescribed. They have also excelled at servicing new prescriptions written for our medications, the new patient starts I just described. The task that remains is grinding through the insurance prior authorization backlog that...

Image source: The Motley Fool. Tuesday, February 24, 2026 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Gary Robb Chief Financial Officer — Atabak Mokari President, Endocrinology Division — Sean Maduck Chief Development Officer — William Guyer President, Oncology Division — Roberto Vieira Atabak Mokari: Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the full year and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-K with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call, other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risk and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available on the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our 2025 revenue was $761 million compared to $675 million in the prior year. We expect our revenue growth to continue and are providing full year 2026 revenue guidance of $900 million to $1 billion. Net income was $99.7 million for the full year 2025 compared to $141.2 million in the prior year. Cash and investments at December 31, 2025, were $532 million, which reflects our acquisition in 2025 of $245 million worth of our common stock pursuant to our stock repurchase program as well as shares acquired upon the exercise of Corcept stock options and the vesting of restricted stock rates. I will now turn the call over to Charlie Robb, our Chief Business Officer. Charlie? Gary Robb: Thanks, Atabak. As many of you know, last Thursday, the Federal Circuit Court of Appeals ruled against us in our lawsuit to stop Teva Pharmaceuticals from marketing a generic version of Korlym in violation of our patents. We believe the court made a mistake. Patents we have asserted as included in Korlym's label and Teva's copy of...

Image source: The Motley Fool. Monday, May 5, 2025 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff President, Endocrinology — Sean Maduck President, Oncology — Roberto Vieira Chief Business Officer — Charles Robb Chief Development Officer — William Guyer Our revenue in the first quarter of 2025 was $157.2 million, compared to $146.8 million in the first quarter of last year. We are reiterating our 2025 revenue guidance of $900 million to $950 million. Net income was $20.5 million in the first quarter of 2025, compared to $27.8 million in the first quarter of last year. Our cash and investments at March 31st were $570.8 million. We acquired $43 million of our common stock in the first quarter of 2025 pursuant to our stock repurchase program, the net exercise of stock options by Corcept employees and the net vesting of restricted stock. I will now turn the call over to Sean Maduck, President of our Endocrinology division. Sean? Sean Maduck: Thank you, Atabak. We are on the cusp of a new diagnosis and treatment paradigm for patients with hypercortisolism. For many years, most physicians reserved both screening and treatment for the most physically obvious cases of hypercortisolism. Over the last 15 years, published data supported the identification and the treatment across a broader spectrum of disease. Screening for hypercortisolism has increased and it is driving rapid patient growth in our business. I’m certain that this increase in screening is just beginning. I’ve never been more confident in both our current and future growth prospects, and most important, our potential to help many, many patients for years to come. We now know that patients with hypercortisolism exist in every medical practice. More and more physicians are starting to recognize that, too. To put this in perspective, our new prescriber base has grown at a record rate for five straight quarters, and the number of Korlym prescriptions in the first quarter of this year was almost double what we saw in the same period last year. Both our prescriber base and our patient base are growing rapidly, and we expect growth to accelerate. In 2023 and 2024, we amplified our efforts to educate physicians about hypercortisolism and Korlym. We also increased the size of our sales force and we will continue to grow that team to reach and serve all our potential customers. We currently have 125 cl...